Drug Profile
TPIV 100
Alternative Names: TPIV-100Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Mayo Clinic
- Developer Marker Therapeutics Inc; Mayo Clinic
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II HER2 positive breast cancer
Most Recent Events
- 02 Mar 2021 Phase-I/II development is ongoing in USA
- 20 Feb 2020 Phase-II clinical trials in HER2-positive-breast-cancer(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Intradermal)
- 18 Dec 2019 Mayo Clinic plans a phase II trial in Breast cancer (Late-stage disease, Second-line therapy or greater, Combination therapy) in USA in January 2020 (Intradermal) (NCT04197687)